ITPC’s Global Survey on Access to and Quality of HIV Treatment and Care
ITPC’s Global Survey on Access to and Quality of HIV Treatment and Care focused on barriers to quality HIV care...
Read more about ITPC’s Global Survey on Access to and Quality of HIV Treatment and Care
ITPC backs fight against replacement of HIV drug dolutegravir in El Salvador
For more than a month, people living with HIV in El Salvador’s capital city have been surviving a shortage of...
Read more about ITPC backs fight against replacement of HIV drug dolutegravir in El Salvador
Watch What Matters: Communities transforming healthcare
When the Community Treatment Observatories (CTOs) were first set up in 11 countries in West Africa to monitor access to...
Read more about Watch What Matters: Communities transforming healthcare
ITPC’s IAS 2019 highlights!
The International AIDS Society (IAS) conferences are always bursting with events, announcements and debates, and the 10th International Conference on...
Read more about ITPC’s IAS 2019 highlights!
AIDS activists demand access to important cryptococcal meningitis drug
At the 10th International HIV Conference on Science (IAS 2019) taking place in Mexico City, AIDS activists protested Gilead’s inaction...
Read more about AIDS activists demand access to important cryptococcal meningitis drug
The right to health is compulsory: Time for action on dolutegravir – now!
Why Algeria, Azerbaijan, Belarus, Brazil, Bulgaria, China, Colombia, Kazakhstan, Mexico, Romania, Russia, and Turkey must issue compulsory licences on dolutegravir...
Read more about The right to health is compulsory: Time for action on dolutegravir – now!
Old wine in new bottles: Keep TRIPS-plus provisions out of the RCEP FTA!
Intellectual property barriers, which would hinder access to affordable medicines, have supposedly been removed from the draft RCEP free-trade agreement...
Read more about Old wine in new bottles: Keep TRIPS-plus provisions out of the RCEP FTA!
Truvada for PrEP. Gilead grilled at US congressional hearing
The USA is being charged $70 per pill for a drug, yet tax payers largely funded the research. Thanks to...
Read more about Truvada for PrEP. Gilead grilled at US congressional hearing
Activists file post-grant opposition challenging a patent preventing purchase of cheaper treatment for hepatitis C
GTPI has presented an argument to the Brazilian Patent Office (INPI) to invalidate the patent granted for the drug daclatasvir....
Read more about Activists file post-grant opposition challenging a patent preventing purchase of cheaper treatment for hepatitis C
Advocacy in Ukraine results in drastic price reduction for HIV drug, raltegravir
The All-Ukrainian Network of People Living with HIV/AIDS (the Network) has received an official letter from Merck, dated 15 March...
Read more about Advocacy in Ukraine results in drastic price reduction for HIV drug, raltegravir